Abatacept Reverses Subclinical Arthritis in Patients with High-risk to Develop Rheumatoid Arthritis -results from the Randomized, Placebo-controlled ARIAA Study in RA-at Risk Patients

Rech J, Hueber A, Ostergaard M, Tascilar K, Hagen M, Mendez LV, Kleyer A, Krönke G, Simon D, Schönau V, Hueber A, Kleinert S, Baraliakos X, Fleck M, Rubbert-Roth A, Behrens F, Kofler D, Feuchtenberger M, Zaenker M, Voll R, Glaser C, Feist E, Burmester G, Karberg K, Strunk J, Canete JD, Naredo E, Filkova M, Senolt L, Schett G (2021)


Publication Type: Conference contribution

Publication year: 2021

Journal

Publisher: WILEY

City/Town: HOBOKEN

Pages Range: 939-941

Conference Proceedings Title: ARTHRITIS & RHEUMATOLOGY

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Rech, J., Hueber, A., Ostergaard, M., Tascilar, K., Hagen, M., Mendez, L.V.,... Schett, G. (2021). Abatacept Reverses Subclinical Arthritis in Patients with High-risk to Develop Rheumatoid Arthritis -results from the Randomized, Placebo-controlled ARIAA Study in RA-at Risk Patients. In ARTHRITIS & RHEUMATOLOGY (pp. 939-941). HOBOKEN: WILEY.

MLA:

Rech, Jürgen, et al. "Abatacept Reverses Subclinical Arthritis in Patients with High-risk to Develop Rheumatoid Arthritis -results from the Randomized, Placebo-controlled ARIAA Study in RA-at Risk Patients." Proceedings of the ARTHRITIS & RHEUMATOLOGY HOBOKEN: WILEY, 2021. 939-941.

BibTeX: Download